Notify me when INCYTE CORP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 9.9% | $6,295,859 | 4,372,124 | INCYTE CORP | 03 Nov 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|